Navigation Links
Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
Date:7/30/2013

novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' strategic alliance with GlaxoSmithKline, and the discovery, development, activity, therapeutic and commercial potential and safety of ISIS-TTRRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These a
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Disease Control and Neurotoxicity Data To Be Presented ... Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for ... Team to Host Analyst and Investor Briefing to ... SAN FRANCISCO, Calif., May 28 Poniard Pharmaceuticals, ...
... and Melanoma Studies - Conference Call to be Hosted ... Conn., May 28 CuraGen Corporation (Nasdaq: ... data presentations from its ongoing clinical trials of CR011-vcMMAE, ... advanced breast cancer and melanoma at the 2009 Annual ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:3/1/2015)... 2015 A federal court overseeing ... scheduled to go to trial in October has ... to provide testimony regarding the role an Italian ... Profemur device, Bernstein Liebhard LLP comments. According to ... District of Iowa on February 25th, Wright Medical ...
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
(Date:2/28/2015)... A study out of the University ... procedure for the treatment of a hereditary ocular condition ... Authored by Dr. Robert MacLaren, professor of ophthalmology at ... Medical Journal on January 16, 2014 , the study ... disorder that mostly affects men and leads to the ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... researchers have found that a particular resonance pattern in ... its ability to discriminate speech. ,In ... Poeppel and Huan Luo report that the inherent rhythm ... spoken sentences by changing its phase. ,The ...
... American idol winner Kelly Clarkson has revealed that she was ... interview to 'CosmoGirl!' in its August issue, the singer said ... to lose weight for a role in a play. ... thinner...then I'll get the role," Us Weekly quoted Clarkson, as ...
... wine halved in France since the 1950s, the world's number ... its saviour. But while the Chinese and Indians have ... worlds largest, there are those attending the two-yearly event who ... margins in China are not there. It is not ready ...
... a strong work ethic and sense of place appear to ... illness , in that these values may delay them from seeking ... to view their work as a lifelong endeavour, and there is ... it out or not go to the hospital, said Alex Clark, ...
... 50 years of independence this year, the fight against river ... bad news is that the parasite that causes the crippling ... one drug used to treat it. ,River blindness ... by black flies. The worms can cause intense itching, elephantiasis ...
... days is good advice for more reasons than sheer comfort. ... That's the message from the Pennsylvania Medical Society, warning young ... to be avoided at all costs - even if it ... is not an accident," says Marilyn J. Heine, M.D., an ...
Cached Medicine News:Health News:Go for Russia, Not China, Wine Experts Say 2Health News:Go for Russia, Not China, Wine Experts Say 3Health News:Rural Work Ethic Curbs Elderly Heart Care 2Health News:River Blindness Becoming Drug Resistant 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 2Health News:Keep a Cool Head on Hot, Humid Days to Avoid Heat Stroke 3
... Infrapatellar Band uses an aircell ... patellar tendon helping to relieve ... patella tendonitis. Focusing the pressure ... tubercle with less constriction of ...
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: